Our findings indicate synergistic in vitro efficacy of combining simvastatin and irinotecan against diverse GBM lines at nanomolar concentrations, as well as mechanistic convergence on the TGF-β pathway—suggesting a novel therapeutic option for patients with GBM and other TGF-β driven cancers. This evidence concerns the gene TGFB1 and cancer.